Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.

Expert review of anti-infective therapy - 1 Mar 2015

Gamal Nesrine, Vitale Giovanni, Andreone Pietro

Abstract excerpt

Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly reduce the risk of developing cirrhosis, hepatocellular carcinoma and liver-related death. A plethora of new direct antiviral agents have been developed and are being explored in clinical trials. One of the newest members of this family is the NS3/4A protease inhibitor ABT-450. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Naphthylamine
Share to Anilides
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Ritonavir

Share to Uracil

Source

Identifiers

PMID: 25582226
DOI: 10.1586/14787210.2015.1001746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.PMID 25582226Read ↗

New antiviral agents for the treatment of hepatitis C: ABT-450.Semantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450Semantic proximity Read ↗

Sofosbuvir and ABT-450: terminator of hepatitis C virus?Semantic proximity Read ↗

Hepatitis C therapy in non-genotype 1 patients: the near future.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.Semantic proximity Read ↗

Exploratory study of oral combination antiviral therapy for hepatitis C.Semantic proximity Read ↗

Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.Semantic proximity Read ↗

Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.Semantic proximity Read ↗

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.Semantic proximity Read ↗

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.Semantic proximity Read ↗

High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.